Expand all sections

Icatibant

Firazyr

Extended indication Voor de behandeling van de symptomen van aanvallen van erfelijk angio-oedeem bij jongeren en kindere
Therapeutic value No judgement

Product

Active substance Icatibant
Domain Chronic immune diseases
Main indication Other chronic immune diseases
Extended indication Voor de behandeling van de symptomen van aanvallen van erfelijk angio-oedeem bij jongeren en kinderen ouder dan twee jaar.
Proprietary name Firazyr
Manufacturer Shire
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Expected Registration October 2017
Orphan drug No
Additional remarks Indicatie-uitbreiding. Geregistreerd in oktober 2017.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found
Dosage per administration 30 mg

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 1,500.00 - 1,700.00
References Medicijnkosten.nl
Additional remarks €1678,33 per injectie van 30 mg

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.